The sale is small relative to market cap and appears to be part of a pre-arranged 10b5-1 plan, reducing the likelihood of opportunistic insider selling. Monitor for any acceleration of insider sales or changes in the 10b5-1 plan that could signal a shift in management's outlook.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $10.35entry
- T+1 · 13d ago +1.06%α −0.59% · $10.46
- T+5 · 7d ago +52.95%α +53.53% · $15.83
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Beth Hecht, an officer of Xeris Biopharma, filed a Form 144 notice of intent to sell 75,000 shares of common stock with an estimated aggregate market value of $803,250. The shares were acquired through vesting of restricted stock units in January 2025, and the proposed sale is scheduled for November 2, 2026. The filing indicates a pre-existing 10b5-1 trading plan, with prior sales under the plan in August, September, and October 2026.
Key Facts
- Beth Hecht, an officer, filed Form 144 to sell 75,000 shares of XERS common stock.
- Estimated aggregate market value of the proposed sale is $803,250.
- Shares were acquired via vesting of restricted stock units between January 3, 2025 and January 31, 2025.
- The proposed sale date is November 2, 2026.
- The filing references a 10b5-1 trading plan, with prior sales of 16,666 shares each in August, September, and October 2026.
- Xers Biopharma has a market cap of $2.0B; the proposed sale represents approximately 0.04% of market cap.
Financial Impact
Proposed sale of 75,000 shares valued at $803,250, representing about 0.04% of the company's $2.0B market cap.
Risk Factors
- Form 144 is an intent to sell; the sale may not be executed.
- Insider selling, even under a 10b5-1 plan, can be perceived negatively by the market if it is large relative to the insider's holdings or if it occurs ahead of negative news.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010584 |
| Document: 0001950047-26-010584-index.html | 0001950047-26-010584 |
| Document: 0001950047-26-010584.txt | 0001950047-26-010584 |
Track record
25 reports on XERS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +45.52% at T+60 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 Now $16.70 +5.30% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $15.20 Now $16.70 +9.87% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago 3 Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Viewing Entry $10.35 Now $16.70 +61.35% settles Dec 2
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $10.17 Now $16.70 +64.21% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 Now $16.70 +55.93% settles Nov 30
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 Now $16.70 +70.93% ▲ +69.09% +70.36% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 Now $16.70 +64.86% ▲ +5.73% +8.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers